- Home
- INTS vs FGEN Comparison
INTS vs FGEN Comparison
Compare INTS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- FGEN
- Stock Information
- Founded
- INTS 2012
- FGEN 1993
- Country
- INTS United States
- FGEN United States
- Employees
- INTS N/A
- FGEN N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- FGEN Health Care
- Exchange
- INTS Nasdaq
- FGEN Nasdaq
- Market Cap
- INTS 8.0M
- FGEN 33.5M
- IPO Year
- INTS 2023
- FGEN 2014
- Fundamental
- Price
- INTS $0.33
- FGEN $7.26
- Analyst Decision
- INTS Strong Buy
- FGEN Strong Buy
- Analyst Count
- INTS 3
- FGEN 1
- Target Price
- INTS $8.50
- FGEN $250.00
- AVG Volume (30 Days)
- INTS 3.7M
- FGEN 74.1K
- Earning Date
- INTS 08-07-2025
- FGEN 08-05-2025
- Dividend Yield
- INTS N/A
- FGEN N/A
- EPS Growth
- INTS N/A
- FGEN N/A
- EPS
- INTS N/A
- FGEN N/A
- Revenue
- INTS N/A
- FGEN $6,996,000.00
- Revenue This Year
- INTS N/A
- FGEN N/A
- Revenue Next Year
- INTS N/A
- FGEN N/A
- P/E Ratio
- INTS N/A
- FGEN N/A
- Revenue Growth
- INTS N/A
- FGEN N/A
- 52 Week Low
- INTS $0.26
- FGEN $4.50
- 52 Week High
- INTS $5.10
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- INTS 41.29
- FGEN 60.54
- Support Level
- INTS $0.26
- FGEN $5.37
- Resistance Level
- INTS $0.32
- FGEN $5.73
- Average True Range (ATR)
- INTS 0.03
- FGEN 0.49
- MACD
- INTS 0.02
- FGEN 0.27
- Stochastic Oscillator
- INTS 62.56
- FGEN 83.80
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.